not require expensive or specialized equipment. Therefore, prior to any improvements in automated susceptibility testing machines, the disc diffusion method for detecting PRGBS will be useful for clinical microbiological laboratories worldwide.

Acknowledgements
We thank Kumiko K, Yoshie Taki and Yumiko Yoshimura for technical assistance.

Funding
This study was supported by grants H21-Shinkou-Ippan-008 and H24-Shinkou-Ippan-010, from the Ministry of Health, Labor and Welfare, Japan, and, in part, by a research grant for medical science from the Takeda Science Foundation (2012). The third grant covered the cost of editing by Editage, as mentioned in the Transparency declarations section.

Transparency declarations
The authors have no conflicts of interest to declare. The manuscript was edited by Editage, a language editing company.

References

J Antimicrob Chemother 2013
doi:10.1093/jac/dkt009
Advance Access publication 22 January 2013

Ceftaroline in the treatment of concomitant methicillin-resistant and daptomycin-non-susceptible Staphylococcus aureus infective endocarditis and osteomyelitis: case report

Karissa Jongsmab1*, Jeremiah Joson1 and Arash Heidari2

1Department of Clinical Pharmacy, Kern Medical Center, Bakersfield, CA, USA; 2Department of Infectious Diseases, Kern Medical Center, Bakersfield, CA, USA

*Corresponding author. Tel: +1-661-326-2504; Fax: +1-661-326-2502; E-mail: jongsma1@kernmedctr.com

Keywords: salvage therapy, surgery, abscess, intravenous drug user

Sir, A middle-aged male presented to the emergency department with fever and 1 week of sharp right hip pain worsening over the past 2 days. His past medical history included uncontrolled diabetes and chronic active hepatitis C. The patient also had a history of multiple methicillin-resistant Staphylococcus aureus (MRSA) infections, including bacteremia 1 month prior, for which he was treated with vancomycin (MIC ≤0.5–1 mg/L).

Three sets of blood cultures were collected before the patient received a single dose of vancomycin and piperacillin/tazobactam. The blood Gram stain showed Gram-positive cocci. The infectious diseases team was consulted, and given recent vancomycin treatment and recurrent bacteraemia, we recommended high-dose daptomycin (8 mg/kg intravenously every 24 h). Dual therapy with rifampicin was considered, but due to limited in vivo data as well as concomitant hepatic dysfunction, we decided against it.1 Initial blood cultures grew MRSA (3/3 bottles) on hospital day 3, with susceptibility tests showing a daptomycin MIC of 0.38 mg/L (Etest; AB Biodisk, Solna, Sweden) and a vancomycin MIC of 1 mg/L by broth microdilution. Repeat blood cultures on day 4 (2/2 bottles) showed no growth. On hospital day 2, a transoesophageal echocardiogram (TEE) demonstrated no evidence of vegetations. On day 3, a contrast CT of the hip showed bone and retroperitoneal abscesses along with evidence highly suggestive of osteomyelitis. An MRI was less conclusive about the presence of early osteomyelitis. The surgical team was consulted and recommended that the patient to undergo CT-guided drainage of the retroperitoneal abscess as opposed to any surgical treatment, citing difficult surgical access, a high-risk patient with comorbidities and likelihood of the abnormal synovium in radiographic studies being reactive synovitis as opposed to osteomyelitis and septic arthritis. Drainage proceeded on day 7, though there was continued debate about the diagnosis and need for surgical intervention.
The patient continued to have episodes of fever, which had been occurring since admission. On day 14, the patient developed leucocytosis and blood cultures were drawn, which grew MRSA. The MIC of vancomycin increased to 2 mg/L, with that of daptomycin remaining at 0.38 mg/L.

Since the patient continued to be symptomatic, irrigation and debridement was scheduled, but due to surgeon availability issues this was not performed until hospital day 19. A sample was obtained during the procedure and cultured, and on day 22, after >2 weeks of treatment with daptomycin, MRSA grew with a daptomycin MIC of 3 mg/L [daptomycin-non-susceptible S. aureus (DNSSA)]. The primary cause of the daptomycin failure was most likely a delay in incision and drainage of the abscesses. Experimental osteomyelitis models have shown selective resistance with daptomycin monotherapy, which possibly contributed to the resistance in this case. Daptomycin was discontinued and, unfortunately, vancomycin was restarted over the weekend.

After the patient became bacteraemic on day 14, we recommended a TEE, which was ordered but not performed until day 23. Lesions were found on the left coronary cusp (LCC) and the tricuspid valve, consistent with endocarditis. Vancomycin was discontinued, since current expert opinion states alternative antitricuspid valve, consistent with endocarditis. Vancomycin was most likely a delay in incision and drainage of the abscesses. Experimental osteomyelitis models have shown selective resistance with daptomycin monotherapy, which possibly contributed to the resistance in this case. Daptomycin was discontinued and, unfortunately, vancomycin was restarted over the weekend.

Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia

Marcus Y. Chen1,2†, Kerrie Stevens3†, Robin Tideman4, Angelo Zaia3, Takehiro Tomita3, Christopher K. Fairley1,2, Monica Lahra4,5, David Whiley6,7 and Geoff Hogg3

1Melbourne Sexual Health Centre, Alfred Health, Carlton, Victoria 3053, Australia; 2Melbourne School of Population Health, University of Melbourne, Victoria 2010, Australia; 3Microbiological Diagnostic Unit Public Health Laboratory, Melbourne University, Parkville, Victoria 3010, Australia; 4WHO Collaborating Centre for Sexually Transmitted Diseases, SEALS Microbiology, The Prince of Wales Hospital, Randwick, New South Wales 2031, Australia; 5University of New South Wales, Kensington, New South Wales 2052, Australia; 6The University of Queensland, St Lucia, Queensland 4072, Australia; 7Queensland Paediatric Infectious

**Transparency declarations**

None to declare.

**References**


J Antimicrob Chemother 2013
doi:10.1093/jac/dkt017
Advance Access publication 6 February 2013

Funding

This study was carried out as part of our routine work.